CELLECTIS S.A.

History

Year	Detail
1999	Cellectis is founded in Paris, France.
2000	Institut Pasteur grants exclusive rights to Nine patent families, including several based on Andre Choulika’s research, the genesis of the gene editing field.
2005	Cellectis enables the industrial production of nucleases, and Cellectis research teams have provided proof of the in vivo efficacy of meganucleases.
2010	The Company has founded Cellectis plant sciences Inc. (now Calyxt, Inc.) and acquired all assets of CytoPulse Inc., based in Maryland, The acquisition included Hybrimune electrofusion technology and PulseAgile technology for RNA transfection by electroporation.
2011	Cellectis has received the exclusive license of TAL nuclease patents from the University of Minnesota.
2014	Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration to develop immunotherapies against selected targets in the field of oncology. Cellectis and Servier announce collaboration in allogeneic cell therapy to develop and commercialize novel product candidates targeting leukemia and other potential tumors.
2015	Cellectis announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will present encouraging data from a first-in-man clinical use of UCART19.
2019	The Company announced the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate had been dosed at The University of Texas MD Anderson Cancer Center.
2020	It has announced that the first patient had been dosed at The University of Texas MD Anderson Cancer Center in AMELI-01, a Phase 1 clinical trial that uses a new UCART123 construct with an optimized production process and new IND number from the FDA.
2022	Cellectis started a materials manufacturing facility in Paris, France, and a UCART GMP manufacturing facility in Raleigh, North Carolina, U.S.
2023	The Company has announced strategic collaboration and Investment Agreements with AstraZeneca.